WASHINGTON UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF MEDICINE

• Questions or comments
• Search

My primary research interest is to develop and conduct clinical trials for patients with newly diagnosed or relapsed lymphoma. Over the last several years, I have developed a special interest in the treatment of relapsed Hodgkin lymphoma (HL). While the overall prognosis of patients with newly diagnosed HL remains excellent, those with relapsed disease have less than a 50% chance of cure. In 2007, I published results of a Phase II trial of a pre-transplant salvage regimen including gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed HL. Overall response rates were 70% and the treatment was well tolerated and less toxic than other salvage regimens. I have worked closely with the pharmaceutical company Seattle Genetics over the last 5 years testing anti-CD30 based targeted therapy for HL, initially the monoclonal antibody SGN-30 (Bartlett et al. Blood 2008) and more recently the immunotoxin SGN-35, an antibody-tubulin inhibitor conjugate (Younes et al. ASCO 2008). In collaboration with Washington University faculty member Todd Fehniger, we are currently testing the efficacy of lenalidomide for relapsed HL in a multi-center Phase II trial. I also serve as the co-chair of a recently activated Phase II cooperative group trial of the anti-CD80 antibody Galiximab for relapsed HL.

We also have a strong portfolio of cooperative group and industry sponsored trials available for most subtypes of non-Hodgkin lymphoma (NHL) including: newly diagnosed and relapsed mantle cell lymphoma (high dose therapy and stem cell transplant as first line therapy and a Phase II trial of lenalidomide and bortezomib for relapsed disease), diffuse large cell lymphoma (Phase III study of DA-EPOCH-R vs. R-CHOP for untreated large cell and two trials for relapsed large cell, R-ICE +/- SGN-40 and a Phase II study of YM155, a survivin inhibitor), relapsed PTCL (Preliterate + gemcitabine), newly diagnosed PTCL, cutaneous T-cell lymphoma (forodesine, pralatrexate), and relapsed follicular lymphoma (Phase II study of bendamustine, bortezomib, rituximab and a Phase II study of lenalidomide and rituximab).

In collaboration with Washington University faculty member Amanda Cashen, a tumor bank for fresh/frozen lymphoma tissue was recently activated and we are hopeful this will allow additional correlative studies with Washington University laboratory scientists.

Education

1978	BS Chemical Engineering, Stanford University, Stanford, CA
1979	MS Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA
1986	MD, Washington University, St. Louis, MO

Post-graduate Training

1986-1987	Internship in Internal Medicine, University of California, San Francisco, CA
1987-1989	Residency in Internal Medicine, University of California, San Francisco, CA
1989-1990	Chief Resident in Internal Medicine, University of California, San Francisco, CA
1990-1994	Postdoctoral Fellowship in Medical Oncology, Stanford University, Stanford, CA

Academic Positions

1994-2000	Assistant Professor, Washington University, St. Louis, MO
2000-present	Associate Professor of Medicine, Washington University, St. Louis, MO

Appointments & Committees

1994-present	Staff Physician, Barnes-Jewish Hospital
1998	Electronic Medical Record Committee
1999-2001	Protocol Review and Monitoring Committee, Siteman Cancer Center
2001-present	Chairman, Quality Assurance and Safety Monitoring Committee, Siteman Cancer Center

Board Certification

1989	Diplomate, American Board of Internal Medicine
1993	Board Certified: Medical Oncology
2003	Recertification: Medical Oncology

Honors & Awards

1978	Phi Beta Kappa
1986	Alpha Omega Alpha
1992	Lymphoma Research Foundation Fellowship
1996-1999	American Cancer Society Career Development Award

Professional Societies, Organizations & Appointments

1989-present	American College of Physicians
1994-present	American Society of Hematology
1994-present	Member, Cancer and Leukemia Group B (CALGB)
1995-present	American Society of Clinical Oncology
1998-present	Washington University CALGB Principal Investigator
1998-present	Member, CALGB Lymphoma Core Committee
2000-2002	CALGB Executive Committee
2003-2004	American Society of Hematology Abstract Reviewer
2003-2005	American Society of Clinical Oncology Program Committee, Adult Leukemia/Lymphoma Subcommittee
2004-present	Editorial Board, Journal of Clinical Oncology
2006-present	Member, CALGB Membership Committee
2007-present	Scientific Program Committee, American Society of Clinical Oncology

Updated: July 14, 2008